Activation of PXR inhibits tumorigenicity of colon cancer cells [58], and PXR agonists may have potentials in inhibiting inflammation related diseases [59]; besides, we also identified that IPA did not precipitate tumor growth in vivo, indicating that IPA might be employed in clinical settings without potential pitfalls. This evidence concerns the gene NR1I2 and neoplasm.